Question-and-Answer Session
Operator
Thank you. (Operator instructions) Our first question comes from Mr. Jami Rubin with Goldman Sachs.
Jami Rubin - Goldman Sachs
Hi. Mrs. Jami Rubin. Anyway, very good quarter. I wanted to ask you Jim as long as we have you on the call to talk sort of big picture strategically. Now that you have made the Medarex acquisition, I'm wondering if you can talk about other areas that might be of interest. Does this fulfill the requirements for the oncology phase for Bristol, and what other areas or therapeutic categories would interest you and also on the Medarex deal, can you share with us what the royalty payments are for Simponi, Stelara, and the third product? And then I just wanted to switch gears for a second on Plavix in Europe, we understand that Plavix, generic Plavix was approved by the CPMP [ph] and if you could sort of just give us a sense for what's happening in Europe with generic Plavix. I know it's now just in Germany but if you anticipate that it spreads and how we should think about that going forward. Thanks.
Jim Cornelius
Okay, Jami thank you for that expansive set of questions, let me try and address strategically what again the String of Pearls means for us. First of all, I think in this quarter and our net cash position indicates we are not done with the String of Pearls. I think our interest in the various therapeutic classes remains the same and after celebrating yesterday, we will today off but we will start tomorrow on looking for other pearls. The second part was on Medarex. All right, the royalty we will pass that to Lamberto.
Lamberto Andreotti
Okay, yes, as far as I remember the royalties that Medarex gets from third parties are in the low-single digits. You also asked about situation of Plavix in the EU and the pretty complex situation with generic competitors being approved or being reduced. Let me start with Germany. There is still one (inaudible) that was launched in August 2008 and it is marketed by two generic companies of Germany, Ratiopharm and (inaudible).
(inaudible) is indicated in a limited number of indications that are present more or less half of the clopidogrel sales or (inaudible) in Germany and as far as I know by May 2009 they have taken about 30% -- 34% of market share in units from us and Sanofi. There are a number of generic marketing authorization applications that got THMP opinion recently. Some did opt for full clopidogrel indication. Some of these are only for the (inaudible) indication.
- To read the full transcript on Seeking Alpha, click here »
